These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18363511)

  • 1. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
    Athyros VG; Kakafika A; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Investig Drugs; 2008 Apr; 17(4):445-9. PubMed ID: 18363511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
    Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C
    PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
    Rennings AJ; Stalenhoef A
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
    Bellanger N; Julia Z; Villard EF; El Khoury P; Duchene E; Chapman MJ; Fournier N; Le Goff W; Guerin M
    Atherosclerosis; 2012 Mar; 221(1):160-8. PubMed ID: 22265126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
    de Grooth GJ; Kuivenhoven JA; Stalenhoef AF; de Graaf J; Zwinderman AH; Posma JL; van Tol A; Kastelein JJ
    Circulation; 2002 May; 105(18):2159-65. PubMed ID: 11994249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CETP inhibitors in the treatment of dyslipidemia.
    van der Steeg WA; Kuivenhoven JA; Klerkx AH; Boekholdt SM; Hovingh GK; Kastelein JJ
    Curr Opin Lipidol; 2004 Dec; 15(6):631-6. PubMed ID: 15529021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
    Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.